Brian B Godman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/736610/publications.pdf

Version: 2024-02-01

429 papers

11,833 citations

53 h-index 71685

g-index

449 all docs

449 docs citations

449 times ranked 7169 citing authors

#	Article	IF	CITATIONS
1	Efficacy of Mobile Apps to Support the Care of Patients With Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. JMIR MHealth and UHealth, 2017, 5, e4.	3.7	223
2	Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Services Research, 2010, 10, 153.	2.2	201
3	The â€~Wise List'– A Comprehensive Concept to Select, Communicate and Achieve Adherence to Recommendations of Essential Drugs in Ambulatory Care in Stockholm. Basic and Clinical Pharmacology and Toxicology, 2011, 108, 224-233.	2.5	185
4	Physicians' knowledge, perceptions and behaviour towards antibiotic prescribing: a systematic review of the literature. Expert Review of Anti-Infective Therapy, 2015, 13, 665-680.	4.4	165
5	Policies for biosimilar uptake in Europe: An overview. PLoS ONE, 2017, 12, e0190147.	2.5	153
6	Response to the Novel Corona Virus (COVID-19) Pandemic Across Africa: Successes, Challenges, and Implications for the Future. Frontiers in Pharmacology, 2020, 11, 1205.	3. 5	143
7	Economics of Myocardial Perfusion Imaging in Europeâ€"the EMPIRE study. European Heart Journal, 1999, 20, 157-166.	2.2	142
8	Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. Expert Review of Pharmacoeconomics and Outcomes Research, 2010, 10, 707-722.	1.4	131
9	Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Review of Pharmacoeconomics and Outcomes Research, 2009, 9, 65-83.	1.4	126
10	Ongoing Initiatives to Improve the Quality and Efficiency of Medicine Use within the Public Healthcare System in South Africa; A Preliminary Study. Frontiers in Pharmacology, 2017, 8, 751.	3.5	124
11	Ongoing strategies to improve the management of upper respiratory tract infections and reduce inappropriate antibiotic use particularly among lower and middle-income countries: findings and implications for the future. Current Medical Research and Opinion, 2020, 36, 301-327.	1.9	111
12	Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?. Expert Review of Clinical Pharmacology, 2015, 8, 77-94.	3.1	108
13	Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications. Frontiers in Pharmacology, 2014, 5, 106.	3.5	107
14	Non-prescription sale and dispensing of antibiotics in community pharmacies in Zambia. Expert Review of Anti-Infective Therapy, 2016, 14, 1215-1223.	4.4	102
15	Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets. Frontiers in Public Health, 2018, 6, 328.	2.7	102
16	Ongoing pharmaceutical reforms in France. Applied Health Economics and Health Policy, 2010, 8, 7-24.	2.1	97
17	Strategies to Improve Antimicrobial Utilization with a Special Focus on Developing Countries. Life, 2021, 11, 528.	2.4	95
18	The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications. Pharmacoeconomics, 2017, 35, 1271-1285.	3.3	94

#	Article	IF	Citations
19	Policies to Enhance Prescribing Efficiency in Europe: Findings and Future Implications. Frontiers in Pharmacology, 2010, 1, 141.	3.5	90
20	Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications. Journal of Comparative Effectiveness Research, 2012, 1, 527-538.	1.4	86
21	Point prevalence surveys of health-care-associated infections: a systematic review. Pathogens and Global Health, 2019, 113, 191-205.	2.3	82
22	Soft regulations in pharmaceutical policy making. Applied Health Economics and Health Policy, 2009, 7, 137-147.	2.1	81
23	Personalizing health care: feasibility and future implications. BMC Medicine, 2013, 11, 179.	5.5	81
24	Review of Ongoing Activities and Challenges to Improve the Care of Patients With Type 2 Diabetes Across Africa and the Implications for the Future. Frontiers in Pharmacology, 2020, 11, 108.	3.5	79
25	A multicenter point prevalence survey of antibiotic use in Punjab, Pakistan: findings and implications. Expert Review of Anti-Infective Therapy, 2019, 17, 285-293.	4.4	77
26	Use of Genericsâ€"A Critical Cost Containment Measure for All Healthcare Professionals in Europe?. Pharmaceuticals, 2010, 3, 2470-2494.	3.8	76
27	Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Frontiers in Pharmacology, 2013, 4, 39.	3.5	75
28	Recent National and Regional Drug Reforms in Sweden. Pharmacoeconomics, 2008, 26, 537-550.	3.3	74
29	International Variability in the Reimbursement of Cancer Drugs by Publically Funded Drug Programs. Current Oncology, 2012, 19, 165-176.	2.2	74
30	Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations. European Journal of Clinical Pharmacology, 2013, 69, 73-78.	1.9	74
31	Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries. Expert Review of Pharmacoeconomics and Outcomes Research, 2013, 13, 469-482.	1.4	74
32	Medicine Shortages: Gaps Between Countries and Global Perspectives. Frontiers in Pharmacology, 2019, 10, 763.	3.5	74
33	Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland. Expert Review of Pharmacoeconomics and Outcomes Research, 2012, 12, 125-130.	1.4	72
34	Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review. Pharmacoeconomics, 2015, 33, 905-924.	3.3	72
35	Status of antimicrobial stewardship programmes in Nigerian tertiary healthcare facilities: Findings and implications. Journal of Global Antimicrobial Resistance, 2019, 17, 132-136.	2.2	72
36	Systemic Measures and Legislative and Organizational Frameworks Aimed at Preventing or Mitigating Drug Shortages in 28 European and Western Asian Countries. Frontiers in Pharmacology, 2018, 8, 942.	3.5	70

3

#	Article	IF	Citations
37	Initiatives to reduce nonprescription sales and dispensing of antibiotics: Findings and implications. Journal of Research in Pharmacy Practice, 2017, 6, 120.	0.7	70
38	Influence of demand-side measures to enhance renin–angiotensin prescribing efficiency in Europe: implications for the future. Expert Review of Pharmacoeconomics and Outcomes Research, 2011, 11, 469-479.	1.4	68
39	Assessing Adherence to Antihypertensive Therapy in Primary Health Care in Namibia: Findings and Implications. Cardiovascular Drugs and Therapy, 2017, 31, 565-578.	2.6	68
40	The influence of a sustained multifaceted approach to improve antibiotic prescribing in Slovenia during the past decade: findings and implications. Expert Review of Anti-Infective Therapy, 2015, 13, 279-289.	4.4	67
41	Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment. Health Policy, 2010, 94, 221-229.	3.0	64
42	Antimicrobial stewardship knowledge and perception among physicians and pharmacists at leading tertiary teaching hospitals in Zambia: implications for future policy and practice. Journal of Chemotherapy, 2019, 31, 378-387.	1.5	64
43	COVID-19 pandemic in resource-poor countries: challenges, experiences and opportunities in Ghana. Journal of Infection in Developing Countries, 2020, 14, 838-843.	1.2	64
44	Enhancing the rational use of new medicines across European health care systems. European Journal of Clinical Pharmacology, 2008, 64, 1137-1138.	1.9	63
45	Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications. Expert Review of Pharmacoeconomics and Outcomes Research, 2010, 10, 73-85.	1.4	63
46	Time trends in statin utilisation and coronary mortality in Western European countries. BMJ Open, 2016, 6, e010500.	1.9	63
47	Point prevalence study of antimicrobial use among hospitals across Botswana; findings and implications. Expert Review of Anti-Infective Therapy, 2019, 17, 535-546.	4.4	63
48	Compliance to guidelines for the prescribing of antibiotics in acute infections at Namibia's national referral hospital: a pilot study and the implications. Expert Review of Anti-Infective Therapy, 2017, 15, 713-721.	4.4	62
49	Rapid Assessment of Price Instability and Paucity of Medicines and Protection for COVID-19 Across Asia: Findings and Public Health Implications for the Future. Frontiers in Public Health, 2020, 8, 585832.	2.7	62
50	Validity of World Health Organisation prescribing indicators in Namibia's primary healthcare: findings and implications. International Journal for Quality in Health Care, 2019, 31, 338-345.	1.8	61
51	European countries with small populations can obtain low prices for drugs: Lithuania as a case history. Expert Review of Pharmacoeconomics and Outcomes Research, 2011, 11, 343-349.	1.4	60
52	The impact of law enforcement on dispensing antibiotics without prescription: a multi-methods study from Saudi Arabia. Expert Review of Anti-Infective Therapy, 2020, 18, 87-97.	4.4	60
53	Sale of WHO AWaRe groups antibiotics without a prescription in Pakistan: a simulated client study. Journal of Pharmaceutical Policy and Practice, 2020, 13, 26.	2.4	60
54	Insight into recent reforms and initiatives in Austria: implications for key stakeholders. Expert Review of Pharmacoeconomics and Outcomes Research, 2008, 8, 357-371.	1.4	59

#	Article	IF	CITATIONS
55	Point prevalence survey of antibiotic use and resistance at a referral hospital in Kenya: findings and implications. Hospital Practice (1995), 2018, 46, 128-136.	1.0	59
56	Forecasting drug utilization and expenditure in a metropolitan health region. BMC Health Services Research, 2010, 10, 128.	2.2	58
57	Generic Medicines: Solutions for a Sustainable Drug Market?. Applied Health Economics and Health Policy, 2013, 11, 437-443.	2.1	56
58	The prescribing of generic medicines in Nigeria: knowledge, perceptions and attitudes of physicians. Expert Review of Pharmacoeconomics and Outcomes Research, 2016, 16, 639-650.	1.4	56
59	Medicine shortages and challenges with the procurement process among public sector hospitals in South Africa; findings and implications. BMC Health Services Research, 2020, 20, 234.	2.2	56
60	Antibiotic consumption and antimicrobial resistance in Poland; findings and implications. Antimicrobial Resistance and Infection Control, 2018, 7, 136.	4.1	54
61	Are pharmacists' good knowledge and awareness on antibiotics taken for granted? The situation in Albania and future implications across countries. Journal of Global Antimicrobial Resistance, 2018, 13, 240-245.	2.2	53
62	Antimicrobial point prevalence surveys in two Ghanaian hospitals: opportunities for antimicrobial stewardship. JAC-Antimicrobial Resistance, 2020, 2, dlaa001.	2.1	53
63	Structured pharmacist-led intervention programme to improve medication adherence in COPD patients: A randomized controlled study. Research in Social and Administrative Pharmacy, 2018, 14, 909-914.	3.0	52
64	A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues. Vaccines, 2021, 9, 1387.	4.4	51
65	Antimicrobial Medicines Consumption in Eastern Europeand Central Asia – An Updated Cross-National Study and Assessment of QuantitativeMetrics for Policy Action. Frontiers in Pharmacology, 2018, 9, 1156.	3.5	50
66	Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs. Expert Review of Pharmacoeconomics and Outcomes Research, 2011, 11, 121-129.	1.4	49
67	Pro-Arrhythmic Potential of Oral Antihistamines (H1): Combining Adverse Event Reports with Drug Utilization Data across Europe. PLoS ONE, 2015, 10, e0119551.	2.5	49
68	Potential savings without compromising the quality of care. International Journal of Clinical Practice, 2009, 63, 1320-1326.	1.7	48
69	Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future. Expert Review of Pharmacoeconomics and Outcomes Research, 2009, 9, 475-484.	1.4	48
70	Different initiatives across Europe to enhance losartan utilization post generics: impact and implications. Frontiers in Pharmacology, 2014, 5, 219.	3. 5	48
71	Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways. Frontiers in Pharmacology, 2016, 7, 305.	3 . 5	48
72	Pattern of inappropriate antibiotic use among hospitalized patients in Pakistan: a longitudinal surveillance and implications. Antimicrobial Resistance and Infection Control, 2019, 8, 188.	4.1	48

#	Article	IF	Citations
73	Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 527-540.	1.4	48
74	Antibiotic use in acute respiratory infections in under-fives in Uganda: findings and implications. Expert Review of Anti-Infective Therapy, 2016, 14, 863-872.	4.4	47
75	Fixed dose drug combinations – are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries. Expert Review of Pharmacoeconomics and Outcomes Research, 2020, 20, 1-26.	1.4	47
76	Point prevalence surveys of antimicrobial use: a systematic review and the implications. Expert Review of Anti-Infective Therapy, 2020, 18, 897-910.	4.4	47
77	Key Issues Surrounding Appropriate Antibiotic Use for Prevention of Surgical Site Infections in Low- and Middle-Income Countries: A Narrative Review and the Implications. International Journal of General Medicine, 2021, Volume 14, 515-530.	1.8	47
78	Dispensing of antimicrobials in Kenya: A cross-sectional pilot study and its implications. Journal of Research in Pharmacy Practice, 2018, 7, 77.	0.7	47
79	Insulin Glargine in a Brazilian State: Should the Government Disinvest? An Assessment Based on a Systematic Review. Applied Health Economics and Health Policy, 2014, 12, 19-32.	2.1	46
80	Rapid review of suspected adverse drug events due to remdesivir in the WHO database; findings and implications. Expert Review of Clinical Pharmacology, 2021, 14, 95-103.	3.1	46
81	Antibiotic prescribing patterns at a leading referral hospital in Kenya: A point prevalence survey. Journal of Research in Pharmacy Practice, 2019, 8, 149.	0.7	46
82	Assessment of prescribing practices at the primary healthcare facilities in Botswana with an emphasis on antibiotics: Findings and implications. International Journal of Clinical Practice, 2017, 71, e13042.	1.7	45
83	Health-related quality of life and associated factors among patients with diabetes mellitus in Botswana. Alexandria Journal of Medicine, 2018, 54, 111-118.	0.6	45
84	Determinants of antibiotic prescribing among doctors in a Nigerian urban tertiary hospital. Hospital Practice (1995), 2019, 47, 53-58.	1.0	45
85	Torsadogenic Risk of Antipsychotics: Combining Adverse Event Reports with Drug Utilization Data across Europe. PLoS ONE, 2013, 8, e81208.	2.5	45
86	Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs. Frontiers in Pharmacology, 2014, 5, 109.	3.5	44
87	Prescription patterns and adequacy of blood pressure control among adult hypertensive patients in Kenya; findings and implications. Expert Review of Clinical Pharmacology, 2017, 10, 1263-1271.	3.1	44
88	Inflammatory Bowel Diseases (CrohnÂ's Disease and Ulcerative Colitis): Cost of Treatment in Serbia and the Implications. Applied Health Economics and Health Policy, 2017, 15, 85-93.	2.1	44
89	The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures. Frontiers in Pharmacology, 2020, 11, 591134.	3.5	44
90	Compliance with the primary health care treatment guidelines and the essential medicines list in the management of sexually transmitted infections in correctional centres in South Africa: findings and implications. Expert Review of Anti-Infective Therapy, 2017, 15, 963-972.	4.4	43

#	Article	IF	CITATIONS
91	Compliance to prescribing guidelines among public health care facilities in Namibia; findings and implications. International Journal of Clinical Pharmacy, 2020, 42, 1227-1236.	2.1	43
92	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications. Infection and Drug Resistance, 2020, Volume 13, 4673-4695.	2.7	43
93	Having Your Cake and Eating It. Pharmacoeconomics, 2008, 26, 91-98.	3.3	42
94	Utilisation of the ESMO-MCBS in practice of HTA. Annals of Oncology, 2016, 27, 2134-2136.	1.2	42
95	Prescribing patterns for upper respiratory tract infections: a prescription-review of primary care practice in Kedah, Malaysia, and the implications. Expert Review of Anti-Infective Therapy, 2015, 13, 1547-1556.	4.4	41
96	A review of trials investigating efavirenz-induced neuropsychiatric side effects and the implications. Expert Review of Anti-Infective Therapy, 2016, 14, 377-388.	4.4	41
97	Rapid Assessment of the Potential Paucity and Price Increases for Suggested Medicines and Protection Equipment for COVID-19 Across Developing Countries With a Particular Focus on Africa and the Implications. Frontiers in Pharmacology, 2020, 11, 588106.	3.5	41
98	Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction. Expert Review of Pharmacoeconomics and Outcomes Research, 2009, 9, 569-581.	1.4	40
99	Prevalence of Vitamin D deficiency in Pakistan and implications for the future. Expert Review of Clinical Pharmacology, 2016, 9, 329-338.	3.1	40
100	Prophylactic antibiotics to prevent surgical site infections in Botswana: findings and implications. Hospital Practice (1995), 2018, 46, 97-102.	1.0	40
101	Antimicrobial dispensing practices and determinants of antimicrobial resistance: a qualitative study among community pharmacists in Pakistan. Family Medicine and Community Health, 2019, 7, e000138.	1.6	40
102	Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries?. Frontiers in Pharmacology, 2020, 11, 970.	3.5	39
103	Payers endorse generics to enhance prescribing efficiency: impact and future implications, a case history approach. GaBI Journal, 2012, 1, 69-83.	0.3	39
104	Cost-effectiveness thresholds: methods for setting and examples from around the world. Expert Review of Pharmacoeconomics and Outcomes Research, 2018, 18, 277-288.	1.4	38
105	Pharmacotherapeutic interventions for bipolar disorder type II: addressing multiple symptoms and approaches with a particular emphasis on strategies in lower and middle-income countries. Expert Opinion on Pharmacotherapy, 2019, 20, 2237-2255.	1.8	38
106	Progress on the national action plan of Pakistan on antimicrobial resistance (AMR): a narrative review and the implications. Expert Review of Anti-Infective Therapy, 2022, 20, 71-93.	4.4	38
107	Quality of Life of Patients with Type 1 Diabetes Mellitus Using Insulin Analog Glargine Compared with NPH Insulin: A Systematic Review and Policy Implications. Patient, 2018, 11, 377-389.	2.7	37
108	Pilot study assessing the direct medical cost of treating patients with cancer in Kenya; findings and implications for the future. Journal of Medical Economics, 2018, 21, 878-887.	2.1	37

#	Article	IF	Citations
109	Update of Recent Reforms in Germany to Enhance the Quality and Efficiency of Prescribing of Proton Pump Inhibitors and Lipid-Lowering Drugs. Pharmacoeconomics, 2009, 27, 435-438.	3.3	36
110	CYD-TDV dengue vaccine: systematic review and meta-analysis of efficacy, immunogenicity and safety. Journal of Comparative Effectiveness Research, 2017, 6, 165-180.	1.4	36
111	Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications. BMC Medicine, 2014, 12, 98.	5.5	35
112	General practitioners' knowledge, attitude and prescribing of antibiotics for upper respiratory tract infections in Selangor, Malaysia: findings and implications. Expert Review of Anti-Infective Therapy, 2015, 13, 1-10.	4.4	35
113	Structure and activities of pharmacy and therapeutics committees among public hospitals in South Africa; findings and implications. Expert Review of Clinical Pharmacology, 2017, 10, 1273-1280.	3.1	35
114	Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation. Frontiers in Pharmacology, 2017, 8, 497.	3.5	34
115	The Early Awareness and Alert System in Sweden: History and Current Status. Frontiers in Pharmacology, 2017, 8, 674.	3.5	34
116	A point prevalence survey of antimicrobial utilisation patterns and quality indices amongst hospitals in South Africa; findings and implications. Expert Review of Anti-Infective Therapy, 2021, 19, 1353-1366.	4.4	34
117	Drug promotional activities in Nigeria: impact on the prescribing patterns and practices of medical practitioners and the implications. Hospital Practice (1995), 2018, 46, 77-87.	1.0	33
118	Recent Initiatives in the Republic of Srpska to Enhance Appropriate Use of Antibiotics in Ambulatory Care; Their Influence and Implications. Frontiers in Pharmacology, 2018, 9, 442.	3.5	33
119	Surgical Antimicrobial Prophylaxis Among Pediatric Patients in South Africa Comparing Two Healthcare Settings. Pediatric Infectious Disease Journal, 2019, 38, 122-126.	2.0	33
120	Ongoing and planned activities to improve the management of patients with Type 1 diabetes across Africa; implications for the future. Hospital Practice (1995), 2020, 48, 51-67.	1.0	33
121	Challenges and Innovations Brought about by the COVID-19 Pandemic Regarding Medical and Pharmacy Education Especially in Africa and Implications for the Future. Healthcare (Switzerland), 2021, 9, 1722.	2.0	33
122	Financial incentives linked to self-assessment of prescribing patterns: a new approach for quality improvement of drug prescribing in primary care. Quality in Primary Care, 2009, 17, 179-89.	0.8	33
123	HEALTH TECHNOLOGY PERFORMANCE ASSESSMENT: REAL-WORLD EVIDENCE FOR PUBLIC HEALTHCARE SUSTAINABILITY. International Journal of Technology Assessment in Health Care, 2017, 33, 279-287.	0.5	32
124	Ongoing activities to optimize the quality and efficiency of lipid-lowering agents in the Scottish national health service: influence and implications. Expert Review of Pharmacoeconomics and Outcomes Research, 2018, 18, 655-666.	1.4	32
125	Implications of non-prescription antibiotic sales in China. Lancet Infectious Diseases, The, 2019, 19, 1272-1273.	9.1	32
126	A multicenter point prevalence survey of healthcare–associated infections in Pakistan: Findings and implications. American Journal of Infection Control, 2019, 47, 421-424.	2.3	32

#	Article	IF	CITATIONS
127	Knowledge, Attitude and Practice About Coronavirus Disease (COVID-19) Pandemic and Its Psychological Impact on Students and Their Studies: A Cross-Sectional Study Among Pharmacy Students in Saudi Arabia. Risk Management and Healthcare Policy, 2021, Volume 14, 729-741.	2.5	32
128	European payer initiatives to reduce prescribing costs through use of generics. GaBI Journal, 2012, 1, 22-27.	0.3	32
129	Budget impact analysis of medicines: updated systematic review and implications. Expert Review of Pharmacoeconomics and Outcomes Research, 2016, 16, 257-266.	1.4	31
130	Consumer Willingness to Pay for Dengue Vaccine (CYD-TDV, Dengvaxia \hat{A}^{\otimes}) in Brazil; Implications for Future Pricing Considerations. Frontiers in Pharmacology, 2017, 8, 41.	3.5	31
131	Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and) Tj ETQq1 1 0.784 Review and Meta-Analysis. BioDrugs, 2018, 32, 585-606.	-314 rgBT 4.6	/Overlock I 31
132	Ongoing initiatives to improve the use of antibiotics in Botswana: University of Botswana symposium meeting report. Expert Review of Anti-Infective Therapy, 2018, 16, 381-384.	4.4	31
133	Proposal for a regulation on health technology assessment in Europe – opinions of policy makers, payers and academics from the field of HTA. Expert Review of Pharmacoeconomics and Outcomes Research, 2019, 19, 251-261.	1.4	31
134	Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab. Applied Health Economics and Health Policy, 2020, 18, 5-16.	2.1	31
135	Pricing of oral generic cancer medicines in 25 European countries; findings and implications. GaBI Journal, 2019, 8, 49-70.	0.3	31
136	Price cuts and drug spending in South Korea: The case of antihyperlipidemic agents. Health Policy, 2013, 112, 217-226.	3.0	30
137	Quality of life of patients with Diabetes Mellitus Types 1 and 2 from a referal health centre in Minas Gerais, Brazil. Expert Review of Clinical Pharmacology, 2016, 9, 739-746.	3.1	30
138	Evidence-based public policy making for medicines across countries: findings and implications for the future. Journal of Comparative Effectiveness Research, 2021, 10, 1019-1052.	1.4	30
139	Social Media and COVID-19â€"Perceptions and Public Deceptions of Ivermectin, Colchicine and Hydroxychloroquine: Lessons for Future Pandemics. Antibiotics, 2022, 11, 445.	3.7	30
140	Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directions. Expert Review of Pharmacoeconomics and Outcomes Research, 2012, 12, 661-671.	1.4	29
141	Quality Indicators as a Tool in Improving the Introduction of New Medicines. Basic and Clinical Pharmacology and Toxicology, 2015, 116, 146-157.	2.5	29
142	Knowledge, attitudes and perspective on adverse drug reaction reporting in a public sector hospital in South Africa: baseline analysis. Hospital Practice (1995), 2017, 45, 238-245.	1.0	29
143	Snapshot of antimicrobial stewardship programs in the hospitals of Pakistan: findings and implications. Heliyon, 2019, 5, e02159.	3.2	29
144	Stage at diagnosis and stage-specific survival of breast cancer in Latin America and the Caribbean: A systematic review and meta-analysis. PLoS ONE, 2019, 14, e0224012.	2.5	29

#	Article	IF	Citations
145	Feasibility of using point prevalence surveys to assess antimicrobial utilisation in public hospitals in South Africa: a pilot study and implications. Hospital Practice (1995), 2019, 47, 88-95.	1.0	29
146	Addressing antimicrobial resistance in Nigerian hospitals: exploring physicians prescribing behavior, knowledge, and perception of antimicrobial resistance and stewardship programs. Expert Review of Anti-Infective Therapy, 2021, 19, 537-546.	4.4	29
147	Prescribing restrictions $\hat{a} \in \hat{a}$ a necessary strategy among some European countries to enhance future prescribing efficiency?. Reviews in Health Care, 2012, 3, 5-16.	0.1	29
148	Availability of Medicines in Community Pharmacy to Manage Patients with COVID-19 in Kenya; Pilot Study and Implications. Scholars Academic Journal of Pharmacy, 2021, 10, 36-42.	0.7	28
149	Prescribing of bisphosphonates and antibiotics in Pakistan: challenges and opportunities for the future. Journal of Pharmaceutical Health Services Research, 2015, 6, 111-121.	0.6	27
150	Supporting global antimicrobial stewardship: antibiotic prophylaxis for the prevention of surgical site infection in low- and middle-income countries (LMICs): a scoping review and meta-analysis. JAC-Antimicrobial Resistance, 2020, 2, dlaa070.	2.1	27
151	Knowledge, attitudes and practices of health care professionals towards adverse drug reaction reporting in public sector primary health care facilities in a South African district. European Journal of Clinical Pharmacology, 2020, 76, 991-1001.	1.9	27
152	Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future. Frontiers in Pharmacology, 2016, 7, 197.	3.5	26
153	Activities in Namibia to Limit the Prevalence and Mortality from COVID-19 Including Community Pharmacy Activities and the Implications. Scholars Academic Journal of Pharmacy, 2021, 10, 82-92.	0.7	26
154	Imperative to consider multiple initiatives to maximize prescribing efficiency from generic availability: case history from Abu Dhabi. Expert Review of Pharmacoeconomics and Outcomes Research, 2012, 12, 115-124.	1.4	25
155	Measures to improve angiotensin receptor blocker prescribing efficiency in the UK: findings and implications. Journal of Comparative Effectiveness Research, 2014, 3, 41-51.	1.4	25
156	An Analytical Framework for Assessing Drug and Therapeutics Committee Structure and Work Processes in Tertiary Brazilian Hospitals. Basic and Clinical Pharmacology and Toxicology, 2014, 115, 268-276.	2.5	25
157	Prescribing efficiency of proton pump inhibitors in China: influence and future directions. BMC Health Services Research, 2015, 15, 11.	2.2	25
158	Antimicrobial prescribing and determinants of antimicrobial resistance: a qualitative study among physicians in Pakistan. International Journal of Clinical Pharmacy, 2019, 41, 1348-1358.	2.1	25
159	Integrative Review of Managed Entry Agreements: Chances and Limitations. Pharmacoeconomics, 2020, 38, 1165-1185.	3.3	25
160	Availability and Use of Therapeutic Interchange Policies in Managing Antimicrobial Shortages among South African Public Sector Hospitals; Findings and Implications. Antibiotics, 2020, 9, 4.	3.7	25
161	Assessment of adherence to pneumonia guidelines and its determinants in an ambulatory care clinic in Ghana: findings and implications for the future. JAC-Antimicrobial Resistance, 2021, 3, dlab080.	2.1	25
162	Getting better value from the NHS drug budget. BMJ: British Medical Journal, 2010, 341, c6449-c6449.	2.3	25

#	Article	IF	Citations
163	Evaluation of antihypertensive adherence and its determinants at primary healthcare facilities in rural South Africa. Journal of Comparative Effectiveness Research, 2018, 7, 661-672.	1.4	25
164	Generic olanzapine: health authority opportunity or nightmare?. Expert Review of Pharmacoeconomics and Outcomes Research, 2008, 8, 549-555.	1.4	24
165	Influence of multiple initiatives in Sweden to enhance ARB prescribing efficiency following generic losartan; findings and implications for other countries. International Journal of Clinical Practice, 2013, 67, 853-862.	1.7	24
166	Changes in the Utilization of Venlafaxine after the Introduction of Generics in Sweden. Applied Health Economics and Health Policy, 2013, 11, 383-393.	2.1	24
167	The potential influence of various initiatives to improve rational prescribing for proton pump inhibitors and statins in Belgium. Expert Review of Pharmacoeconomics and Outcomes Research, 2013, 13, 141-151.	1.4	24
168	Evaluating the Treatment Costs for Uncomplicated Malaria at a Public Healthcare Facility in Nigeria and the Implications. PharmacoEconomics - Open, 2017, 1, 185-194.	1.8	24
169	Impact of a pharmacist-driven pharmacovigilance system in a secondary hospital in the Gauteng Province of South Africa. Hospital Practice (1995), 2018, 46, 221-228.	1.0	24
170	Healthcare-associated infections including neonatal bloodstream infections in a leading tertiary hospital in Botswana. Hospital Practice (1995), 2019, 47, 203-210.	1.0	24
171	Antibiotic consumption among hospitalized neonates and children in Punjab province, Pakistan. Expert Review of Anti-Infective Therapy, 2022, 20, 931-939.	4.4	24
172	Essential to increase the use of generics in Europe to maintain comprehensive health care?. Farmeconomia E Percorsi Terapeutici, 2012, 13, 5-20.	0.1	24
173	Management of Children Admitted to Hospitals across Bangladesh with Suspected or Confirmed COVID-19 and the Implications for the Future: A Nationwide Cross-Sectional Study. Antibiotics, 2022, 11, 105.	3.7	24
174	An analysis of policies for cotrimoxazole, amoxicillin and azithromycin use in Namibia's public sector: Findings and therapeutic implications. International Journal of Clinical Practice, 2017, 71, e12918.	1.7	23
175	Knowledge of hypertension and its management among hypertensive patients on chronic medicines at primary health care public sector facilities in South Africa; findings and implications. Expert Review of Cardiovascular Therapy, 2017, 15, 639-647.	1.5	23
176	Drug and therapeutics committees in Nigeria: evaluation of scope and functionality. Expert Review of Clinical Pharmacology, 2018, 11, 1255-1262.	3.1	23
177	Costs in the Treatment of Schizophrenia in Adults Receiving Atypical Antipsychotics: An 11-Year Cohort in Brazil. Applied Health Economics and Health Policy, 2018, 16, 697-709.	2.1	23
178	Assessment of multidrug-resistant tuberculosis (MDR-TB) treatment outcomes in Sudan; findings and implications. Expert Review of Anti-Infective Therapy, 2019, 17, 927-937.	4.4	23
179	Implementation and monitoring of decisions by pharmacy and therapeutics committees in South African public sector hospitals. Expert Review of Clinical Pharmacology, 2019, 12, 159-168.	3.1	23
180	Prospective Risk Assessment of Medicine Shortages in Europe and Israel: Findings and Implications. Frontiers in Pharmacology, 2020, 11, 357.	3.5	23

#	Article	IF	Citations
181	Compliance with South Africa's Antimicrobial Resistance National Strategy Framework: are we there yet?. Journal of Chemotherapy, 2021, 33, 21-31.	1.5	23
182	A multicentre point prevalence survey of hospital antibiotic prescribing and quality indices in the Kurdistan regional government of Northern Iraq: the need for urgent action. Expert Review of Anti-Infective Therapy, 2021, 19, 805-814.	4.4	23
183	Utilisation, Availability and Price Changes of Medicines and Protection Equipment for COVID-19 Among Selected Regions in India: Findings and Implications. Frontiers in Pharmacology, 2020, 11, 582154.	3.5	23
184	Co-Infections, Secondary Infections, and Antimicrobial Use in Patients Hospitalized with COVID-19 during the First Five Waves of the Pandemic in Pakistan; Findings and Implications. Antibiotics, 2022, 11, 789.	3.7	23
185	Influence of Patient Co-Payments on Atypical Antipsychotic Choice in Poland. Applied Health Economics and Health Policy, 2011, 9, 101-110.	2.1	22
186	Drug Pricing in South Korea. Applied Health Economics and Health Policy, 2017, 15, 447-453.	2.1	22
187	Ongoing initiatives in Azerbaijan to improve the use of antibiotics; findings and implications. Expert Review of Anti-Infective Therapy, 2018, 16, 77-84.	4.4	22
188	The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future. Frontiers in Public Health, 2021, 9, 671961.	2.7	22
189	Variations in the Consumption of Antimicrobial Medicines in the European Region, 2014–2018: Findings and Implications from ESAC-Net and WHO Europe. Frontiers in Pharmacology, 2021, 12, 639207.	3.5	22
190	SASOCP position statement on the pharmacist's role in antibiotic stewardship 2018. Southern African Journal of Infectious Diseases, 2018, 33, 28-35.	0.5	22
191	Co-infections and antimicrobial use among hospitalized COVID-19 patients in Punjab, Pakistan: findings from a multicenter, point prevalence survey. Pathogens and Global Health, 2022, 116, 421-427.	2.3	22
192	Clinical Effectiveness and Safety of Analog Glargine in Type 1 Diabetes: A Systematic Review and Meta-Analysis. Diabetes Therapy, 2016, 7, 241-258.	2.5	21
193	Statin use in Brazil: findings and implications. Current Medical Research and Opinion, 2018, 34, 1809-1817.	1.9	21
194	Introduction to drug utilization research., 2016,, 1-12.		20
195	A pilot study evaluating the prescribing of ceftriaxone in hospitals in Ghana: findings and implications. Hospital Practice (1995), 2017, 45, 143-149.	1.0	20
196	Predictors of Multidrug-Resistant Tuberculosis (MDR-TB) in Sudan. Antibiotics, 2019, 8, 90.	3.7	20
197	A Cost Analysis of Haemodialysis and Peritoneal Dialysis for the Management of End-Stage Renal Failure At an Academic Hospital in Pretoria, South Africa. PharmacoEconomics - Open, 2019, 3, 631-641.	1.8	20
198	Risks in Antibiotic Substitution Following Medicine Shortage: A Health-Care Failure Mode and Effect Analysis of Six European Hospitals. Frontiers in Medicine, 2020, 7, 157.	2.6	20

#	Article	IF	CITATIONS
199	Prevalence of self-medication for acute respiratory infections in young children in namibia: Findings and implications. Journal of Research in Pharmacy Practice, 2019, 8, 220.	0.7	20
200	Assessment of active pharmaceutical ingredients in drug registration procedures in Pakistan: implications for the future. GaBI Journal, 2016, 5, 156-163.	0.3	20
201	Initiatives to enhance renin–angiotensin prescribing efficiency in Austria: impact and implications for other countries. Expert Review of Pharmacoeconomics and Outcomes Research, 2010, 10, 199-207.	1.4	19
202	Initiatives Across Countries to Reduce Antibiotic Utilisation and Resistance Patterns: Impact and Implications., 2017,, 539-576.		19
203	The long-term costs for treating multiple sclerosis in a 16-year retrospective cohort study in Brazil. PLoS ONE, 2018, 13, e0199446.	2.5	19
204	Consumer willingness to pay for a hypothetical Zika vaccine in Brazil and the implications. Expert Review of Pharmacoeconomics and Outcomes Research, 2019, 19, 473-482.	1.4	19
205	Changes in availability, utilization, and prices of medicines and protection equipment for COVID-19 in an Urban population of Northern Nigeria. Journal of Research in Pharmacy Practice, 2021, 10, 17.	0.7	19
206	Patent expiry and costs for anticancer medicines for clinical use. GaBI Journal, 2017, 6, 105-106.	0.3	19
207	A national, multicentre, web-based point prevalence survey of antimicrobial use and quality indices among hospitalised paediatric patients across South Africa. Journal of Global Antimicrobial Resistance, 2022, 29, 542-550.	2.2	19
208	Differences in utilization rates between commercial and administrative databases: implications for future health-economic and cross-national studies. Expert Review of Pharmacoeconomics and Outcomes Research, 2016, 16, 149-152.	1.4	18
209	Availability and Affordability of Drugs With a Conditional Approval by the European Medicines Agency; Comparison of Korea With Other Countries and the Implications. Frontiers in Pharmacology, 2018, 9, 938.	3.5	18
210	A systematic review and metaâ€analysis of the use of reninâ€angiotensin system drugs and COVIDâ€19 clinical outcomes: What is the evidence so far?. Pharmacology Research and Perspectives, 2020, 8, e00666.	2.4	18
211	Mapping of Current Obstacles for Rationalizing Use of Medicines (CORUM) in Europe: Current Situation and Potential Solutions. Frontiers in Pharmacology, 2020, 11, 144.	3.5	18
212	A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing. Applied Health Economics and Health Policy, 2013, 11, 79-82.	2.1	17
213	Assessment of medication adherence among type 2 diabetic patients in Quetta city, Pakistan. Postgraduate Medicine, 2017, 129, 637-643.	2.0	17
214	The Assessment for Disinvestment of Intramuscular Interferon Beta for Relapsing-Remitting Multiple Sclerosis in Brazil. Pharmacoeconomics, 2018, 36, 161-173.	3.3	17
215	Effectiveness of community-based DOTS strategy on tuberculosis treatment success rates in Namibia. International Journal of Tuberculosis and Lung Disease, 2019, 23, 441-449.	1.2	17
216	Initiatives to reduce postoperative surgical site infections of the head and neck cancer surgery with a special emphasis on developing countries. Expert Review of Anticancer Therapy, 2019, 19, 81-92.	2.4	17

#	Article	IF	CITATIONS
217	Empowering hypertensive patients in south africa to improve their disease management: A pharmacist-led intervention. Journal of Research in Pharmacy Practice, 2019, 8, 208.	0.7	17
218	Prevalence, Knowledge and Potential Determinants of COVID-19 Vaccine Acceptability Among University Students in the United Arab Emirates: Findings and Implications. Journal of Multidisciplinary Healthcare, 2022, Volume 15, 81-92.	2.7	17
219	Influence of lifting prescribing restrictions for losartan on subsequent sartan utilization patterns in Austria: implications for other countries. Expert Review of Pharmacoeconomics and Outcomes Research, 2012, 12, 809-819.	1.4	16
220	Patterns of drugs prescribed for dental outpatients in Nigeria: findings and implications. Acta Odontologica Scandinavica, 2017, 75, 496-506.	1.6	16
221	Economic and epidemiological impact of dengue illness over 16 years from a public health system perspective in Brazil to inform future health policies including the adoption of a dengue vaccine. Expert Review of Vaccines, 2018, 17, 1123-1133.	4.4	16
222	Projecting Pharmaceutical Expenditure in EU5 to 2021: Adjusting for the Impact of Discounts and Rebates. Applied Health Economics and Health Policy, 2018, 16, 803-817.	2.1	16
223	Realâ€world evaluation of the impact of statin intensity on adherence and persistence to therapy: A Scottish populationâ€based study. British Journal of Clinical Pharmacology, 2020, 86, 2349-2361.	2.4	16
224	Development of a web-based application to improve data collection of antimicrobial utilization in the public health care system in South Africa. Hospital Practice (1995), 2021, 49, 184-193.	1.0	16
225	A multicentre point prevalence study of antibiotics utilization in hospitalized patients in an urban secondary and a tertiary healthcare facilities in Nigeria: findings and implications. Expert Review of Anti-Infective Therapy, 2022, 20, 297-306.	4.4	16
226	The impact of South Korea's new drug-pricing policy on market competition among off-patent drugs. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 1007-1014.	1.4	15
227	Ten-year kidney transplant survival of cyclosporine- or tacrolimus-treated patients in Brazil. Expert Review of Clinical Pharmacology, 2016, 9, 991-999.	3.1	15
228	Polypharmacy among the elderly in the Republic of Srpska: extent and implications for the future. Expert Review of Pharmacoeconomics and Outcomes Research, 2016, 16, 609-618.	1.4	15
229	Liver enzyme elevations in a cohort of HIV/AIDS patients on first-line antiretroviral therapy in Namibia: Findings and implications. Alexandria Journal of Medicine, 2018, 54, 49-56.	0.6	15
230	Ongoing initiatives within the Scottish National Health Service to affect the prescribing of selective serotonin reuptake inhibitors and their influence. Journal of Comparative Effectiveness Research, 2019, 8, 535-547.	1.4	15
231	Prescribing patterns of physicians working in both the direct and indirect treatment sectors in Iran; findings and implications. Journal of Pharmaceutical Health Services Research, 2019, 10, 407-413.	0.6	15
232	Statin prescription among patients with type 2 diabetes in Botswana: findings and implications. BMC Endocrine Disorders, 2020, 20, 36.	2.2	15
233	Ongoing efforts to improve the management of patients with diabetes in Bangladesh and the implications. Hospital Practice (1995), 2021, 49, 266-272.	1.0	15
234	Using mystery shoppers to determine practices pertaining to antibiotic dispensing without a prescription among community pharmacies in South Africa—a pilot survey. JAC-Antimicrobial Resistance, 2022, 4, dlab196.	2.1	15

#	Article	IF	Citations
235	Generic atypical antipsychotic drugs in Belgium: their influence and implications. Journal of Comparative Effectiveness Research, 2013, 2, 551-561.	1.4	14
236	Implementation of clinical guidelines in Brazil: should academic detailing be used?. Journal of Pharmaceutical Health Services Research, 2016, 7, 105-115.	0.6	14
237	Effect of changing from first- to second-line antiretroviral therapy on renal function: a retrospective study based on data from a single health facility in Namibia. Expert Review of Anti-Infective Therapy, 2016, 14, 777-783.	4.4	14
238	Consumer willingness to pay for a hypothetical chikungunya vaccine in Brazil and the implications. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, 22, 513-520.	1.4	14
239	Assessment of antimicrobial use and prescribing practices among pediatric inpatients in Zimbabwe. Journal of Chemotherapy, 2020, 32, 456-459.	1.5	14
240	Impact of Delisting ARBs, Apart from Losartan, on ARB Utilisation Patterns in Denmark: Implications for Other Countries. Applied Health Economics and Health Policy, 2013, 11, 677-685.	2.1	13
241	Potential to Enhance the Prescribing of Generic Drugs in Patients with Mental Health Problems in Austria; Implications for the Future. Frontiers in Pharmacology, 2012, 3, 198.	3.5	13
242	Analysis of the influence of recent reforms in China: cardiovascular and cerebrovascular medicines as a case history to provide future direction. Journal of Comparative Effectiveness Research, 2014, 3, 371-386.	1.4	13
243	Comparative effectiveness of adalimumab and etanercept for rheumatoid arthritis in the Brazilian Public Health System. Journal of Comparative Effectiveness Research, 2016, 5, 539-549.	1.4	13
244	Cost-effectiveness of vildagliptin for people with type 2 diabetes mellitus in Brazil; findings and implications. Expert Review of Pharmacoeconomics and Outcomes Research, 2017, 17, 109-119.	1.4	13
245	Glycaemic, blood pressure and low-density lipoprotein-cholesterol control among patients with diabetes mellitus in a specialised clinic in Botswana: a cross-sectional study. BMJ Open, 2019, 9, e026807.	1.9	13
246	Availability and price changes of potential medicines and equipment for the prevention and treatment of COVID-19 among pharmacy and drug stores in Bangladesh; findings and implications. Bangladesh Journal of Medical Science, 0, , .	0.2	13
247	Current utilization patterns for long-acting insulin analogues including biosimilars among selected Asian countries and the implications for the future. Current Medical Research and Opinion, 2021, 37, 1529-1545.	1.9	13
248	Antimicrobial Stewardship Activities in Public Healthcare Facilities in South Africa: A Baseline for Future Direction. Antibiotics, 2021, 10, 996.	3.7	13
249	Comparative persistence of anti-tumor necrosis factor therapy in ankylosing spondylitis patients: a multicenter international study. Current Medical Research and Opinion, 2020, 36, 677-686.	1.9	13
250	Are specific initiatives required to enhance prescribing of generic atypical antipsychotics in Scotland?: International implications. International Journal of Clinical Practice, 2013, 67, 170-180.	1.7	12
251	The impact of the †Better Care Better Value†prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for treating hypertension in the UK primary care setting: longitudinal quasi-experimental design. BMC Health Services Research. 2015. 15. 367.	2.2	12
252	The clinical effectiveness of insulin glargine in patients with Type I diabetes in Brazil: findings and implications. Journal of Comparative Effectiveness Research, 2017, 6, 519-527.	1.4	12

#	Article	IF	Citations
253	Policy Change and the National Essential Medicines List Development Process in Brazil between 2000 and 2014: Has the Essential Medicine Concept been Abandoned?. Basic and Clinical Pharmacology and Toxicology, 2018, 122, 402-412.	2.5	12
254	Predictors of tuberculosis treatment success under the DOTS program in Namibia. Expert Review of Respiratory Medicine, 2018, 12, 979-987.	2.5	12
255	Effectiveness and safety of insulin glargine <i>versus</i> detemir analysis in patients with type 1 diabetes: systematic review and meta-analysis. Therapeutic Advances in Endocrinology and Metabolism, 2018, 9, 241-254.	3.2	12
256	Knowledge regarding medicines management of type 2 diabetes amongst patients attending a Community Health Centre in South Africa. Journal of Pharmaceutical Health Services Research, 2019, 10, 13-28.	0.6	12
257	Challenges facing drug utilization research in the Latin American region. Pharmacoepidemiology and Drug Safety, 2020, 29, 1353-1363.	1.9	12
258	Acceptability and willingness to pay for a hypothetical vaccine against SARS CoV-2 by the Brazilian consumer: a cross-sectional study and the implications. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, 22, 119-129.	1.4	12
259	Indicator of access to medicines in relation to the multiple dimensions of access. Journal of Comparative Effectiveness Research, 2019, 8, 1027-1041.	1.4	12
260	Combating COVID-19: Lessons learnt particularly among developing countries and the implications. Bangladesh Journal of Medical Science, 0, , .	0.2	12
261	Ongoing activities to influence the prescribing of proton pump inhibitors within the Scottish National Health Service: their effect and implications. GaBI Journal, 2018, 7, 142-151.	0.3	12
262	Possible ways to enhance renin–angiotensin prescribing efficiency: Republic of Serbia as a case history?. Journal of Comparative Effectiveness Research, 2012, 1, 539-549.	1.4	11
263	Initiatives to improve prescribing efficiency for drugs to treat Parkinson's disease in Croatia: influence and future directions. Expert Review of Pharmacoeconomics and Outcomes Research, 2012, 12, 373-384.	1.4	11
264	Multilevel Analysis of the Influence of Patients' and General Practitioners' Characteristics on Patented Versus Multiple-Sourced Statin Prescribing in France. Applied Health Economics and Health Policy, 2013, 11, 205-218.	2.1	11
265	Quality and efficiency of statin prescribing across countries with a special focus on South Africa; findings and future implications. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 323-330.	1.4	11
266	Medicines dispensers' knowledge on the implementation of an artemisinin-based combination therapy policy for the treatment of uncomplicated malaria in Tanzania. Journal of Pharmaceutical Health Services Research, 2017, 8, 227-233.	0.6	11
267	Utilization and Expenditure of Anti-cancer Medicines in Kosovo: Findings and Implications. PharmacoEconomics - Open, 2018, 2, 423-432.	1.8	11
268	Clinical and Financial Implications of Medicine Consumption Patterns at a Leading Referral Hospital in Kenya to Guide Future Planning of Care. Frontiers in Pharmacology, 2018, 9, 1348.	3.5	11
269	Impact of a Clinical Pharmacist Intervention on Medicine Costs in Patients with Chronic Obstructive Pulmonary Disease in India. PharmacoEconomics - Open, 2020, 4, 331-342.	1.8	11
270	Formulary Management Activities and Practice Implications Among Public Sector Hospital Pharmaceutical and Therapeutics Committees in a South African Province. Frontiers in Pharmacology, 2020, 11, 1267.	3.5	11

#	Article	IF	Citations
271	Antibiotic resistance and sensitivity pattern of Metallo- \hat{l}^2 -Lactamase Producing Gram-Negative Bacilli in ventilator-associated pneumonia in the intensive care unit of a public medical school hospital in Bangladesh. Hospital Practice (1995), 2020, 48, 128-136.	1.0	11
272	Initiatives to increase the prescribing of low cost generics; the case of Scotland in the international context. Medical Research Archives, $2017, 5, \ldots$	0.2	11
273	Demand of COVID-19 medicines without prescription among community pharmacies in Jodhpur, India: Findings and implications. Journal of Family Medicine and Primary Care, 2022, 11, 503.	0.9	11
274	Do newly marketed generic medicines expand markets using descriptive time series analysis and mixed logit models? Korea as an exemplar and its implications. BMC Health Services Research, 2016, 16, 130.	2.2	10
275	Outcome of the second Medicines Utilisation Research in Africa Group meeting to promote sustainable and appropriate medicine use in Africa. Expert Review of Pharmacoeconomics and Outcomes Research, 2017, 17, 149-152.	1.4	10
276	Experience with developing antibiotic stewardship programs in Serbia: potential model for other Balkan countries?. Journal of Comparative Effectiveness Research, 2018, 7, 247-258.	1.4	10
277	Comparison of Zidovudine and Tenofovir Based Regimens With Regard to Health-Related Quality of Life and Prevalence of Symptoms in HIV Patients in a Kenyan Referral Hospital. Frontiers in Pharmacology, 2018, 9, 984.	3.5	10
278	Discontinuation, persistence and adherence to subcutaneous biologics delivered via a homecare route to Scottish adults with rheumatic diseases: a retrospective study. BMJ Open, 2019, 9, e027059.	1.9	10
279	Generic pregabalin; current situation and implications for health authorities, generics and biosimilars manufacturers in the future. GaBI Journal, 2015, 4, 125-135.	0.3	10
280	Ever-changing landscape of biosimilars in Canada; findings and implications from a global perspective. GaBI Journal, 2019, 8, 93-97.	0.3	10
281	Are prescribing initiatives readily transferable across classes: the case of generic losartan in Scotland?. Quality in Primary Care, 2013, 21, 7-15.	0.8	10
282	Initiative to progress research on medicine utilization in Africa: formation of the Medicines Utilization Research in Africa group. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 607-610.	1.4	9
283	Statin prescribing among hypertensive patients in southwest Nigeria: findings and implications for the future. Journal of Comparative Effectiveness Research, 2016, 5, 281-288.	1.4	9
284	Frequency and evaluation of the perceptions towards caesarean section among pregnant women attending public hospitals in Pakistan and the implications. Hospital Practice (1995), 2017, 45, 104-110.	1.0	9
285	Federal procurement of unlicensed medicines in Brazil; findings and implications. Expert Review of Pharmacoeconomics and Outcomes Research, 2017, 17, 607-613.	1.4	9
286	The use of probiotics as a supplementary therapy in the treatment of patients with asthma: a pilot study and implications. Clinics, 2019, 74, e950.	1.5	9
287	Essential and forgotten antibiotics: An inventory in low- and middle-income countries. International Journal of Antimicrobial Agents, 2019, 54, 273-282.	2.5	9
288	Biosimilars are becoming indispensable in the management of multiple diseases although concerns still exist. Bangladesh Journal of Medical Science, 2020, 20, 5-10.	0.2	9

#	Article	IF	Citations
289	Economic and social cost of epilepsy in Poland: 5-year analysis. European Journal of Health Economics, 2021, 22, 485-497.	2.8	9
290	Pilot Study on the Current Management of Children with COVID-19 In Hospitals in Bangladesh; Findings and Implications. Bangladesh Journal of Medical Science, 0, , 188-198.	0.2	9
291	Can authorities take advantage of the availability of generic atypical antipsychotic drugs? Findings from Sweden and potential implications. Journal of Pharmaceutical Health Services Research, 2013, 4, 139-150.	0.6	8
292	Key Components of Increased Drug Expenditure in South Korea: Implications for the Future. Value in Health Regional Issues, 2015, 6, 14-21.	1.2	8
293	Are generic immunosuppressants safe and effective?. BMJ, The, 2015, 350, h3248-h3248.	6.0	8
294	Patient-related beliefs and adherence toward their medications among the adult hypertensive outpatients in Tanzania. Journal of Comparative Effectiveness Research, 2017, 6, 185-193.	1.4	8
295	Adverse effects of chemotherapy and their management in Pediatric patients with Non-Hodgkin's Lymphoma in Kenya: A descriptive, situation analysis study. Expert Review of Anticancer Therapy, 2019, 19, 423-430.	2.4	8
296	A repeated point prevalence survey of antimicrobial use in specialized cancer care hospital of Pakistan: findings and implications. Hospital Practice (1995), 2019, 47, 149-154.	1.0	8
297	Prescribing trends of inhaler treatments for asthma and chronic obstructive pulmonary disease within a resource-constrained environment in the Scottish national health service: findings and implications. Expert Review of Respiratory Medicine, 2019, 13, 679-689.	2.5	8
298	Proactive risk assessment of vincristine use process in a teaching and referral hospital in Kenya and the implications. Journal of Oncology Pharmacy Practice, 2020, 26, 666-679.	0.9	8
299	Effectiveness of Maintenance Immunosuppression Therapies in a Matched-Pair Analysis Cohort of 16 Years of Renal Transplant in the Brazilian National Health System. International Journal of Environmental Research and Public Health, 2020, 17, 1974.	2.6	8
300	Potential Strategies to Improve Antimicrobial Utilisation in Hospitals in Bangladesh Building on Experiences Across Developing Countries. Bangladesh Journal of Medical Science, 2021, 20, 469-477.	0.2	8
301	Predictors of loss to follow-up of tuberculosis cases under the DOTS programme in Namibia. ERJ Open Research, 2020, 6, 00030-2019.	2.6	8
302	Health authority perspective on biosimilars. GaBI Journal, 2013, 2, 10-11.	0.3	8
303	Can local policies on biosimilars optimize the use of freed resources – experiences from Italy. GaBI Journal, 2020, 9, 183-187.	0.3	8
304	Perceptions of managerial staff on the patient safety culture at a tertiary hospital in South Africa. International Journal of Qualitative Studies on Health and Well-being, 2022, 17, 2066252.	1.6	8
305	Measures to enhance angiotensin-receptor blocker prescribing efficiency in Belgium following generic losartan: impact and implications for the future. Journal of Pharmaceutical Health Services Research, 2013, 4, 173-181.	0.6	7
306	Over-the-counter medicine and dietary supplement consumption among academic youth in Poland. Expert Review of Pharmacoeconomics and Outcomes Research, 2016, 16, 199-205.	1.4	7

#	Article	IF	CITATIONS
307	Managed introduction of new drugs. , 2016, , 210-221.		7
308	The transparency of published health technology assessment-based recommendations on pharmaceutical reimbursement in Poland. Expert Review of Pharmacoeconomics and Outcomes Research, 2017, 17, 385-400.	1.4	7
309	Creating and evaluating an opportunity for medication reconciliation in the adult population of South Africa to improve patient care. Hospital Practice (1995), 2018, 46, 110-120.	1.0	7
310	Prevalence of chronic kidney disease using estimated glomerular filtration rate among diabetes patients attending a tertiary clinic in Botswana. Hospital Practice (1995), 2018, 46, 214-220.	1.0	7
311	Isoniazid acetylation phenotypes in the Sudanese population; findings and implications. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2019, 17, 100120.	1.3	7
312	Did we see it Coming? An Evaluation of the Swedish Early Awareness and Alert System. Applied Health Economics and Health Policy, 2019, 17, 93-101.	2.1	7
313	An evidence-based framework for identifying technologies of no or low-added value (NLVT). International Journal of Technology Assessment in Health Care, 2020, 36, 50-57.	0.5	7
314	Knowledge and Attitude of Physicians Towards the Cost of Commonly Prescribed Medicines: A Case Study in Three Nigerian Healthcare Facilities. Value in Health Regional Issues, 2020, 22, 68-74.	1.2	7
315	Prevalence and treatment of neurological and psychiatric disorders among tertiary hospitals in Pakistan; findings and implications. Hospital Practice (1995), 2020, 48, 145-160.	1.0	7
316	Metabolic Control and Determinants Among HIV-Infected Type 2 Diabetes Mellitus Patients Attending a Tertiary Clinic in Botswana. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2021, Volume 14, 85-97.	2.4	7
317	Availability and accessibility of monoclonal antibodies in Bosnia and Herzegovina: Findings and implications. Medicine Access Point of Care, 2021, 5, 239920262110276.	1.0	7
318	Prevalence and factors associated with anxiety among university students of health sciences in Brazil: findings and implications. Jornal Brasileiro De Psiquiatria, 2021, 70, 99-107.	0.7	7
319	Healthcare Professionals' Knowledge of Pharmacogenetics and Attitudes Towards Antimicrobial Utilization in Zambia: Implications for a Precision Medicine Approach to Reducing Antimicrobial Resistance. Frontiers in Pharmacology, 2020, 11, 551522.	3.5	7
320	Real-world effectiveness of olanzapine and risperidone in the treatment of schizophrenia in Brazil over a 16-year follow-up period; findings and implications. Expert Review of Clinical Pharmacology, 2021, 14, 269-279.	3.1	7
321	Assessing Utilisation and Expenditure on Long-Acting Insulin Analogues in Kenya; Findings and Implications for the Future. Scholars Academic Journal of Pharmacy, 2021, 10, 63-70.	0.7	7
322	Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications. BioMed Research International, 2021, 2021, 1-16.	1.9	7
323	Current management of children with COVID-19 in hospitals in India; Pilot study and findings. Advances in Human Biology, 2022, 12, 16.	0.2	7
324	Challenges and Opportunities With Routinely Collected Data on the Utilization of Cancer Medicines. Perspectives From Health Authority Personnel Across 18 European Countries. Frontiers in Pharmacology, 0, 13, .	3.5	7

#	Article	IF	CITATIONS
325	Exploring Knowledge of Antibiotic Use, Resistance, and Stewardship Programs among Pharmacy Technicians Serving in Ambulatory Care Settings in Pakistan and the Implications. Antibiotics, 2022, 11, 921.	3.7	7
326	Potential drug-drug interactions in paediatric outpatient prescriptions in Nigeria and implications for the future. Expert Review of Clinical Pharmacology, 2016, 9, 1505-1515.	3.1	6
327	Adverse effects of carbamazepine monotherapy among patients in Nigeria: a pilot study and implications. Journal of Comparative Effectiveness Research, 2017, 6, 33-42.	1.4	6
328	Evidence on the cost-effectiveness of lifelong antiretroviral therapy for prevention of mother-to-child transmission of HIV: implications for resource-limited countries in sub-Saharan Africa. Expert Review of Pharmacoeconomics and Outcomes Research, 2017, 17, 459-467.	1.4	6
329	Off-label prescribing for children with chronic diseases in Nigeria; findings and implications. Expert Opinion on Drug Safety, 2017, 16, 981-988.	2.4	6
330	Trends in BRCA testing and socioeconomic deprivation. European Journal of Human Genetics, 2019, 27, 1351-1360.	2.8	6
331	Determinants of glycemic control among diabetes mellitus patients in a tertiary clinic in Gaborone, Botswana: findings and implications. Hospital Practice (1995), 2019, 47, 34-41.	1.0	6
332	Practical Implications From European Hospital Pharmacists on Prospective Risk Assessment for Medicine Shortages. Frontiers in Medicine, 2020, 7, 407.	2.6	6
333	Tenofovir disoproxil fumarate associated nephrotoxicity: a retrospective cohort study at two referral hospitals in Namibia. Pharmacoepidemiology and Drug Safety, 2021, 30, 189-200.	1.9	6
334	COVID-19, health care and self-medication issues in resource-limited settings: Findings and implications based on experiences in Ghana. Advances in Human Biology, 2021, 11, 224.	0.2	6
335	Crizotinib Versus Conventional Chemotherapy in First-Line Treatment for ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Oncology and Therapy, 2021, 9, 505-524.	2.6	6
336	Health authority activities to enhance the quality and efficiency of medicine use and their impact. Advances in Human Biology, 2021, 11, 11.	0.2	6
337	Ongoing initiatives to improve prescribing efficiency in China; statins as a case history. GaBI Journal, 2014, 3, 122-132.	0.3	6
338	Antimicrobial Prescribing Confidence and Knowledge Regarding Drug Resistance: Perception of Medical Students in Malaysia and the Implications. Antibiotics, 2022, 11, 540.	3.7	6
339	A web-based point prevalence survey of antimicrobial use and quality indicators at Raleigh Fitkin Memorial Hospital in the Kingdom of Eswatini and the implications. Hospital Practice (1995), 2022, 50, 214-221.	1.0	6
340	Personalizing healthcare: from genetics through payment to improving care?. Journal of the Royal Society of Medicine, 2013, 106, 41-44.	2.0	5
341	The establishment and expansion of an innovative centre for rational pharmacotherapy—determinants and challenges. International Journal of Health Planning and Management, 2015, 30, 14-30.	1.7	5
342	Antibiotic prescribing practices in the presence of extended-spectrum β-lactamase (ESBL) positive organisms in an adult intensive care unit in South Africa – A pilot study. Alexandria Journal of Medicine, 2018, 54, 541-547.	0.6	5

#	Article	IF	CITATIONS
343	Off-label use of pentazocine and the associated adverse events among pediatric surgical patients in a tertiary hospital in Northern Nigeria: a retrospective chart review. Current Medical Research and Opinion, 2019, 35, 1505-1512.	1.9	5
344	Barriers and facilitators of adherence to antiretroviral treatment at a public health facility in Ghana: a mixed method study. Hospital Practice (1995), 2022, 50, 110-117.	1.0	5
345	Sick leave duration as a potential marker of functionality and disease severity in depression. International Journal of Psychiatry in Clinical Practice, 2022, 26, 406-416.	2.4	5
346	A pilot study regarding the consequences of the COVID-19 pandemic on healthcare education in India and the implications. Advances in Human Biology, 2022, 12, 180.	0.2	5
347	Challenges to the delivery of clinical diabetes services in Ghana created by the COVID-19 pandemic. Journal of Health Services Research and Policy, 0, , 135581962211117.	1.7	5
348	Cost driver analysis of statin expenditure on Australia's Pharmaceutical Benefits Scheme. Expert Review of Pharmacoeconomics and Outcomes Research, 2016, 16, 419-433.	1.4	4
349	Trends in the prescribing of antipsychotic medicines in Pakistan: implications for the future. Current Medical Research and Opinion, 2019, 35, 51-61.	1.9	4
350	Implications of antibiotic exposure among children in low-income and middle-income countries. Lancet Infectious Diseases, The, 2020, 20, 146-147.	9.1	4
351	Poor implementation of the EU clinical trial regulation is a major threat for pragmatic trials in European countries. Epidemiology and Psychiatric Sciences, 2020, 29, e126.	3.9	4
352	Drug utilization review of tramadol hydrochloride in a regional hospital in South Africa; findings and implications. Hospital Practice (1995), 2020, 48, 92-99.	1.0	4
353	Strategies to improve the availability of medicines in primary health care in Brazil: findings and implications. Journal of Comparative Effectiveness Research, 2021, 10, 243-253.	1.4	4
354	Influence of pharmaceutical services organization on the availability of essential medicines in a public health system. Journal of Comparative Effectiveness Research, 2021, 10, 519-532.	1.4	4
355	Consumer willingness to pay for a hypothetical Chagas disease vaccine inÂBrazil: a cross-sectional study and the implications. Journal of Comparative Effectiveness Research, 2021, 10, 659-672.	1.4	4
356	Validity of Pneumonia Severity Assessment Scores in Africa and South Asia: A Systematic Review and Meta-Analysis. Healthcare (Switzerland), 2021, 9, 1202.	2.0	4
357	Ongoing initiatives to improve the prescribing of medicines across sectors and the implications. Advances in Human Biology, 2020, 10, 85.	0.2	4
358	Antibiotic consumption at community pharmacies: A multicenter repeated prevalence surveillance using WHO methodology. Medicine Access Point of Care, 2021, 5, 239920262110647.	1.0	4
359	COVID-19 and the impact on the education of healthcare professionals across countries with a particular focus on developing countries. Bangladesh Journal of Medical Science, 2022, 21, 221-232.	0.2	4
360	Multisystem Inflammatory Syndrome of a Neonate From a COVID-19-Infected Mother: A Case Report. Cureus, 2022, 14, e23046.	0.5	4

#	Article	IF	CITATIONS
361	Health-Care professionals' knowledge and practice regarding disposal of medicines in primary health-care facilities in South Africa: Impact and implications. Journal of Research in Pharmacy Practice, 2021, 10, 185.	0.7	4
362	Review of ongoing initiatives to improve prescribing efficiency in China; angiotensin receptor blockers as a case history. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 157-169.	1.4	3
363	Comparing twice- versus four-times daily insulin in mothers with gestational diabetes in Pakistan and its implications. Journal of Comparative Effectiveness Research, 2016, 5, 453-459.	1.4	3
364	Adjustments of medication dosages in patients with renal impairment in Botswana; findings and implications to improve patient care. Hospital Practice (1995), 2019, 47, 231-240.	1.0	3
365	Impact of EU risk assessment process and administrative regulations for manufacturers of combined hormonal contraceptive prescribing. An analysis of developments in Germany and the implications. Current Medical Research and Opinion, 2019, 35, 697-704.	1.9	3
366	Nature and sources of poisoning in patients admitted to a referral hospital in Gaborone, Botswana; findings and implications. Hospital Practice (1995), 2020, 48, 100-107.	1.0	3
367	Funding and Service Organization to Achieve Universal Health Coverage for Medicines: An Economic Evaluation of the Best Investment and Service Organization for the Brazilian Scenario Frontiers in Pharmacology, 2020, 11, 370.	3.5	3
368	Prevalence rate of spontaneously reported adverse events and determinants of serious adverse events amongst three outpatient care settings in ghana: findings and implications. Advances in Human Biology, 2021, 11, 97.	0.2	3
369	Compliance to hypertensive prescribing guidelines and blood pressure control in elderly patients in Namibia: findings and implications. Journal of Pharmaceutical Health Services Research, 2021, 12, 53-60.	0.6	3
370	A cross-sectional study of the quality of life of patients living with type 1 diabetes treated with insulin glargine and neutral protamine Hagedorn insulin and the implications. Journal of Pharmaceutical Health Services Research, 2021, 12, 332-342.	0.6	3
371	Budget impact analysis of medicines: estimated values versus real-world evidence and the implications. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, , 1-11.	1.4	3
372	Access to medicines in the Brazilian Unified Health System's primary health care: assessment of a public policy. Journal of Comparative Effectiveness Research, 2021, 10, 869-879.	1.4	3
373	Poverty and Cardiovascular Diseases in Sub-Saharan Africa. , 0, , .		3
374	Willingness to pay for a hypothetical malaria vaccine inÂBrazil: a cross-sectional study and the implications. Journal of Comparative Effectiveness Research, 2022, 11, 263-274.	1.4	3
375	EVALUATION OF DRUG USE INDICATORS FOR NON-COMMUNICABLE DISEASES IN PAKISTAN. Acta Poloniae Pharmaceutica, 2016, 73, 787-94.	0.1	3
376	Impact of the COVID-19 pandemic on dental and medical education in Bangladesh: a pilot study and the implications. Bangladesh Journal of Medical Science, 2022, 21, 444-454.	0.2	3
377	Editorial: Emerging Markets' Health and Pharmaceutical Sectors at the Dawn of a Potential Global Financial Crisis of early 2020s. Frontiers in Pharmacology, 2022, 13, 907612.	3.5	3
378	Trends in Antihypertensive Medicine Utilization in the Republic of Srpska, Bosnia and Herzegovina: An Eleven-Year Follow-Up. Frontiers in Pharmacology, 0, 13, .	3.5	3

#	Article	IF	CITATIONS
379	The impact of the COVID-19 pandemic lockdown measures on the prescribing trends and utilization of opioids in the English primary care setting: segmented-liner regression analysis. Expert Review of Clinical Pharmacology, $0, , .$	3.1	3
380	Evaluation of antibiotic prescribing for ambulatory patients seeking primary dental care services in a public hospital in Ghana: a clinical audit study. JAC-Antimicrobial Resistance, 2022, 4, .	2.1	3
381	PP062â€"Variable approaches in europe to the availability of generic losartan; implications for the future. Clinical Therapeutics, 2013, 35, e36-e37.	2.5	2
382	Authors' Reply to Dr. Malerbi: "Insulin Glargine in a Brazilian State: Should the Government Disinvest?― Applied Health Economics and Health Policy, 2014, 12, 561-563.	2.1	2
383	VP25 African Countries Are Working Together To Enhance Medicine Use. International Journal of Technology Assessment in Health Care, 2017, 33, 157-158.	0.5	2
384	Public health psychopharmacology: a new research discipline comes of age?. Epidemiology and Psychiatric Sciences, 2018, 27, 24-28.	3.9	2
385	Authors' response to the comments to "Structured pharmacist-led intervention programme to improve medication adherence in COPD patients: A randomized controlled study― Research in Social and Administrative Pharmacy, 2018, 14, 402-403.	3.0	2
386	Reported needs of information resources, research tools, connectivity and infrastructure among African Pharmacological Scientists to improve future patient care and health. Expert Review of Clinical Pharmacology, 2019, 12, 481-489.	3.1	2
387	Effect of TDF-containing regimens on creatinine clearance in HIV patients in Namibia with a baseline CrCl <60ml/min; findings and implications. Hospital Practice (1995), 2020, 48, 35-40.	1.0	2
388	Profiles of patients on warfarin anticoagulation therapy in a leading tertiary referral hospital in Kenya; findings and implications for Kenya. Expert Review of Cardiovascular Therapy, 2020, 18, 165-173.	1.5	2
389	Alanine transaminase and hemoglobin appear to predict the occurrence of antituberculosis medication hepatotoxicity; findings and implications in Botswana. Expert Review of Anti-Infective Therapy, 2021, 19, 379-391.	4.4	2
390	The Budget Impact of Monoclonal Antibodies Used to Treat Metastatic Colorectal Cancer in Minas Gerais, Brazil. Applied Health Economics and Health Policy, 2021, 19, 557-577.	2.1	2
391	The response to COVID 19 across countries and the implications for future pandemics. Bangladesh Journal of Medical Science, 0, , 7-14.	0.2	2
392	Antibiotics' susceptibility patterns of bacterial isolates causing lower respiratory tract infections in ICU patients at referral hospitals in Namibia. Hospital Practice (1995), 2021, 49, 356-363.	1.0	2
393	â€∢Key findings regarding COVID 19 in Bangladesh and wider and their implications. Bangladesh Journal of Medical Science, 0, , 199-205.	0.2	2
394	Role of Health Technology Assessment in Pharmaceutical Market Access in Developed Countries. , 2018, , 223-254.		2
395	Assessing smoking cessation services and pharmacotherapy in Namibia: findings and implications for future policy initiatives. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, 22, 699-710.	1.4	2
396	Examining the uptake of predictive BRCA testing in the UK; findings and implications. European Journal of Human Genetics, 2021, 29, 699-708.	2.8	2

#	Article	IF	CITATIONS
397	Access to community pharmacy services for people with disabilities: Barriers, challenges, and opportunities. Research in Social and Administrative Pharmacy, 2022, 18, 2711-2713.	3.0	2
398	Key characteristics including sex, sexual orientation and internet use associated with worse mental health among university students in Brazil and implications. Journal of Public Health, 2022, 44, e487-e498.	1,8	2
399	Adoption of new therapies in the treatment of Hepatitis: a verification of the accuracy of budget impact analysis to guide investment decisions. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, , 1-13.	1.4	2
400	Prevalence and Factors Associated With Caesarean Delivery in Nepal: Evidence From a Nationally Representative Sample. Cureus, 2021, 13, e20326.	0.5	2
401	PHP49 Developing Risk Sharing Arrangements – Potential for Brazil and Implications. Value in Health, 2011, 14, A557.	0.3	1
402	Initiatives in South Africa to enhance the prescribing of generic proton pump inhibitors: findings and implications. Journal of Comparative Effectiveness Research, 2015, 4, 123-131.	1.4	1
403	The need for cost-effective choices to treat patients with bipolar 1 disorders including asenapine. Journal of Medical Economics, 2015, 18 , $871-873$.	2.1	1
404	Switching among Equivalents in Chronic Cardiovascular Therapies: â€~Real World' Data from Italy. Basic and Clinical Pharmacology and Toxicology, 2016, 118, 63-69.	2.5	1
405	Drug utilization and health policy. , 2016, , 203-209.		1
406	Health system perspectives., 2016,, 328-335.		1
407	Non-guideline-recommended prescribing of proton pump inhibitors: implications for the future and reducing over usage. Current Medical Research and Opinion, 2017, 33, 2085-2087.	1.9	1
408	Antimicrobial utilization research and activities in Botswana, the past, present and the future. Expert Review of Anti-Infective Therapy, 2019, 17, 759-762.	4.4	1
409	Health equity and the usage of atypical antipsychotics within the Brazilian national health system: findings and implications. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 743-751.	1.4	1
410	Editorial: New Horizons in Health-Promoting Technologies: From Development to Rational Use. Frontiers in Pharmacology, 2020, $11,1180$.	3 . 5	1
411	Evaluation of the clinical practice of aminoglycoside use in paediatric patients in Kenya: findings and implications for lower-middle income countries. JAC-Antimicrobial Resistance, 2020, 2, dlz087.	2.1	1
412	Key patient related factors in the management of inflammatory bowel disease. Journal of Medical Economics, 2020, 23, 1606-1609.	2.1	1
413	Structured Expert Judgement for Decisions on Medicines Policy and Management. Profiles in Operations Research, 2021, , 419-439.	0.4	1
414	Potential strategies to reduce inappropriate prescribing and dispensing of antimicrobials in Bangladesh building on the experiences in other developing countries. Bangladesh Journal of Medical Science, 2021, 20, 700-706.	0.2	1

#	Article	IF	CITATIONS
415	Enhancing Choices Regarding the Administration of Insulin Among Patients With Diabetes Requiring Insulin Across Countries and Implications for Future Care. Frontiers in Pharmacology, 2021, 12, 794363.	3.5	1
416	Global article collection: essential reads from around the world. Journal of Medical Economics, 2022, 25, 864-869.	2.1	1
417	Management of drugs in a health care system. , 2016, , 222-230.		0
418	PP022 New Models Are Needed To Optimize The Management Of New Medicines. International Journal of Technology Assessment in Health Care, 2017, 33, 79-80.	0.5	0
419	Utility of medicines information leaflets in hypertensive care in a setting with low health literacy: A cross-sectional study. Medicine Access Point of Care, 2020, 4, 239920262091003.	1.0	0
420	Pharmacists' clinical knowledge and practice in the safe use of contraceptives: real knowledge vs. self-perception and the implications. BMC Medical Education, 2021, 21, 430.	2.4	0
421	Prevalence and characteristics of medicine use among pregnant women in a Kenyan hospital. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO3-12-28.	0.0	0
422	Medicines Availability among Hypertensive Patients in Primary Health Care Facilities in a Rural Province in South Africa: Findings and Implications. Journal of Research in Pharmacy Practice, 2020, 9, 181-185.	0.7	0
423	A Review of the Evidence on Attitudes, Perceived Impacts and Motivational Factors for European Member State Collaboration for Pricing and Reimbursement of Medicines: Time for the EEA Member States to Apply Their Experience and Expertise in Evidence-Based Decision Making to Their Current Pharmaceutical Policy Challenges, Frontiers in Pharmacology, 2021, 12, 666405.	3. 5	0
424	Evaluation of Namibia's antiretroviral therapy guidelines' recommendations for switching from first-line to second-line, using predictors of first-line treatment failure: an exploratory study. Expert Review of Anti-Infective Therapy, 2021, , 1-7.	4.4	0
425	A Cross-Sectional Study of Quality of Life Among Brazilian Adults With Type 1 Diabetes Treated With Insulin Glargine: Findings and Implications. Clinical Diabetes, 0, , .	2.2	0
426	Editorial: New Horizons in Health-Promoting: From Methods to Implementation Science. Frontiers in Pharmacology, 2021, 12, 830957.	3.5	0
427	Acceptability and Consumer Willingness to pay for a hypothetical HIV vaccine in Northern Brazil: A cross-sectional study and the implications. Journal of HIV/AIDS and Social Services, 0, , 1-22.	0.7	0
428	Survival Analysis of COPD Patients in a 13-Year Nationwide Cohort Study of the Brazilian National Health System. Frontiers in Big Data, 2021, 4, 788268.	2.9	0
429	The global impact of the COVID-19 pandemic on the education of healthcare professionals, especially in low- and middle-income countries. Advances in Human Biology, 2022, .	0.2	O